



RECEIVED  
CENTRAL FAX CENTER

SEP 27 2004

## Patent Technology Center 1600

### Facsimile Transmission

To:                      Name:                                      CENTRAL FAX  
                            Company:  
                            Fax Number:                                      703-872-9306  
                            Voice Phone:

From:                    Name:  
                            Official Fax Number:                                      (703) 872-9306  
                            Official After Final Fax Number:                                      (703) 872-9307  
                            Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

---

---

Date and time of transmission: Monday, September 27, 2004 1:22:16 PM  
Number of pages including this cover sheet: 04

---

**FACSIMILE COVER SHEET**  
**SALIWANCHIK, LLOYD & SALIWANCHIK**

A Professional Association  
2421 N.W. 41st Street  
Suite A-1  
Gainesville, FL 32606

Telephone (352) 375-8100  
Facsimile (352) 372-5800

**RECEIVED**  
**CENTRAL FAX CENTER**

SEP 27 2004

**EXAMINER:** Taofiq A. Solola, Ph.D., J.D. **FROM:** David R. Saliwanchik

**COMPANY:** U.S. Patent Office  
Art Unit 1614

**DATE:** September 24, 2004

**FAX NO.:** (571) 273-0709

**NO. OF PAGES**  
**(INCLUDING COVER SHEET):** 3

**SUBJECT/MESSAGE:**

Serial No. 10/799,546; filed March 11, 2004  
Attorney Docket No. ARYX-113XCD1

1. Terminal Disclaimer (2 pages).

**THIS IS AN OFFICIAL DOCUMENT!**

---

*The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named below. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.*

---

**If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.**

H:\DOC\FAXCOVER\PTO\SOLOLA-1614.DOC\RES\la

RECEIVED  
CENTRAL FAX CENTER

SEP 27 2004

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

Sept. 24, 2004  
David Saliwanchik  
David R. Saliwanchik, Patent Attorney

TERMINAL DISCLAIMER  
Patent Application  
Docket No. ARYX-113XCD1  
Serial No. 10/799,546

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Taofiq A. Solola, Ph.D., J.D.  
Art Unit : 1614  
Applicants : Pascal Druzgala  
Serial No : 10/799,546  
Filed : March 11, 2004  
Conf. No. : 7812  
For : Novel Compounds for Treatment of Arrhythmia, Synthesis, and Methods of Use

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Petitioner, ARYx Therapeutics, is the owner of the entire interest in and to the instant application. The Petitioner hereby disclaims, except as provided below, the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as shortened by any terminal disclaimer filed prior to grant, of U.S. Patent No. 6,710,070, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent be the same as the legal title to the above-referenced patent, this agreement to run with any patent granted on the above-identified application and to be binding on the grantee, its successors or assigns.

H:\DOC\PTO\Terminal-disc\ARYX-113XCD1-070.doc\DNB/an


In making the above disclaimer, the petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of the above-listed application in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, if found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer filed prior to the grant of the patent.

The undersigned has reviewed all the evidentiary documents accompanying or referred to in the instant Terminal Disclaimer and it is certified that, to the best of the undersigned's knowledge and belief, title is in the Petitioner identified above.

The undersigned is the attorney of record.

I authorize you to charge the amount of \$55.00 (small entity) to Deposit Account No. 19-0065.

Respectfully submitted,



David R. Saliwanchik

Patent Attorney

Reg. No. 31,794

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address : 2421 N.W. 41st Street  
Suite A-1  
Gainesville, FL 32606

DRS/la